Lilly reports 93% constant-currency China growth and 55% international incretin share

Eli Lilly's incretin franchise is expanding rapidly overseas, according to analyst summaries of the company's latest disclosures. China revenue grew 93% in constant currency, and Lilly's incretin drugs now hold about 55% of the international market for that drug class ^[1]. The China growth followed Mounjaro's addition to that country's national reimbursement drug list in January 2026 ^[1].

The same disclosures show a tradeoff familiar to US patients: much higher sales volume paired with lower prices per prescription. Lilly's realized prices outside the United States fell 36% ^[1]. Company-wide, realized prices dropped 13% in the second quarter of 2026, a decline the company says was more than offset by 60% volume growth ^[1]. Overall quarterly revenue reached $22.974 billion, up 47.67% year over year, with Mounjaro alone contributing $9.94 billion, a 91% increase from the prior year ^[1]. Lilly's incretin franchise generated roughly $14.87 billion of that quarter's total revenue ^[1].

These figures come from third-party financial analysis of Lilly's reported results, not from a company press release included in the sources reviewed here. The 24/7 Wall St. summary frames the international share and China growth figures as evidence that Lilly's runway extends well beyond the US market ^[1]. A separate industry piece on Lilly's pipeline strategy did not include additional detail on the China pricing dynamics ^[2].

Why it matters for patients

For patients in the United States, these numbers describe a company whose finances increasingly depend on selling more units at lower unit prices, both at home and abroad ^[1]. That pattern has already played out domestically: Lilly's overall realized prices fell 13% in the most recent quarter even as volume climbed sharply ^[1]. Whether that dynamic eventually shows up in US list prices, insurance coverage terms, or manufacturing capacity is not addressed in the sources reviewed here.

The reimbursement change in China matters mainly as a signal of how governments elsewhere are managing incretin drug costs, by negotiating lower prices in exchange for covering far more patients. The sources do not say whether US payers, including Medicare or private insurers, are pursuing a similar strategy in response to Lilly's China experience. A separate program, the Medicare GLP-1 Bridge Program, is described elsewhere in the same reporting as covering an estimated 20 million eligible Americans at $50 per month starting July 1, 2026, but the sources here do not connect that program directly to the China pricing pattern ^[1].

Investors and market analysts are watching whether falling realized prices, both in the US and internationally, will continue to be offset by rising volume. The 24/7 Wall St. analysis lists "realized-price declines accelerating past 13%" as a reason it might turn more cautious on Lilly's stock, a threshold framed around company performance rather than patient costs ^[1]. For patients, the practical takeaway is that global expansion and reimbursement deals like China's may increase how many people worldwide can access these drugs, even as the per-prescription price Lilly collects keeps falling.

What happens next

The sources reference a few dated milestones tied to Lilly's broader pipeline, though not directly to the China or international incretin figures. Lilly has said it plans to submit a Biologics License Application for retatrutide, a triple-agonist drug, in the first quarter of 2027 ^[1]. Foundayo, Lilly's oral GLP-1 medication, had expanded to 36,000 prescribers as of the most recent disclosures ^[1]. No specific future date is given in the sources for further updates on China reimbursement policy or international incretin market share.